Checks a score for choosing surgery first in advanced ovarian cancer
Studies a scoring tool to predict surgery outcomes in adults with advanced ovarian cancer.
Key facts
- Who runs it
- Cukurova University
- Where
- Adana, TürkiyeSee the site
- Trial code
- Registry title
- Cukurova Score Validation Study
- Status
- Recruiting
- People taking part
- 130 people, planned
- Started
- 30 May 2024
- Expected to end
- Mar 2027
- Type of study
- Observational
- Record updated
- 29 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. It checks whether the Cukurova score predicts the result of primary cytoreduction surgery.
- Age
- 18 years and over (up to 100 years)
- Sex
- Women
- Disease stage
- Stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer, confirmed by pathology; advanced disease suspected on imaging
Main reasons for not taking part
- Stage I-II epithelial ovarian, fallopian tube or peritoneal cancer
- Non-epithelial ovarian cancer
- Benign or borderline ovarian tumors
- Metastatic ovarian tumors
- Under 18 years old or not agreeing to take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- 18 years old and over
- Suspected advanced ovarian/fallopian tube/ primary peritoneal carcinomatosis on imaging
- Pathologically confirmed Stage III-IV epithelial ovarian cancer/fallopian tube/ primary peritoneal carcinomatosis
- Consent to participate in the study
Who cannot take part
- Stage I-II epithelial ovarian/fallopian tube/peritoneal cancer
- Nonepithelial Ovarian Cancer
- <18 years old
- Benign Ovarian tumors
- Borderline Ovarian Tumors
- Metastatic Ovarian Tumors
- Rejecting to Participate in the Study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in Türkiye
- Cukurova UniversityAdana, TürkiyeContact: Ghanim Khatib, MDTaking people
About the trial
What the trial wants to find out
Despite significant advancements in imaging technologies, surgical techniques, chemotherapeutic regimens, and treatment strategies in recent years, ovarian cancer continues to remain the most deadly gynecological malignancy. Approximately 90% of ovarian cancers originate from the coelomic epithelium or modified mesothelial cells and are classified as epithelial ovarian cancers. The majority of patients with epithelial ovarian cancer (70-80%) present in advanced stages. The primary treatment for advanced-stage (stage 3-4) disease consists of primary cytoreductive surgery followed by adjuvant chemotherapy. Cytoreductive surgery aims to remove all visible tumor implants regardless of the extent of the disease and achieve no visible residual tumor (complete cytoreduction, R0) at the end of the surgery. In cases where R0 cannot be achieved (due to poor general condition and/or extensive tumor that cannot be completely excised surgically), the option of neoadjuvant chemotherapy followed by interval cytoreductive surgery is considered. Primary cytoreductive surgery is still the preferred option and is considered a quality indicator for centers performing advanced-stage ovarian cancer surgeries. Despite advancements in surgery, the decision for interval surgery following primary surgery or neoadjuvant chemotherapy is often based on the surgeon's experience, imaging results, and clinic preferences. Various methods and scores have been published and applied to predict which patients are suitable for primary surgery.
Read full original descriptionShow less
The Cukurova score developed in our clinic conceptualizes prioritizing surgical procedures using radiological imaging and diagnostic exploratory laparoscopy to achieve complete cytoreduction in harmony with the patient's clinical and performance status, rather than focusing solely on tumor burden. The score showed high success rates for complete cytoreduction and also was useful in terms of predicting the morbidity and mortality. However, the Cukurova score study was conducted in single center. Validation of scores in centers with different capacities is expected to facilitate their widespread use and acceptance. Therefore, in this study, the investigators plan to conduct a validation study of the score in a total of 20 centers in Turkey, including our center. This study aims to evaluate the validity of the Cukurova score in predicting outcomes of primary cytoreduction in advanced ovarian cancer patients and thus determining the decision for primary cytoreductive surgery or neoadjuvant chemotherapy followed by interval cytoreductive surgery.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cukurova Score Validation Study in Prediction of Primary Cytoreduction in Advanced Ovarian Cancer
- Plain-language title
- Checks a score for choosing surgery first in advanced ovarian cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06378905, who can take part
- Record updated
- 29 August 2024